EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET
Company Participants
George Elston - CFO
Nancy Lurker - President and CEO
Jay Duker - COO
Scott Jones - CCO
Conference Call Participants
Georgi Yordanov - Cowen
Yatin Suneja - Guggenheim Securities
Jennifer Kim - Cantor Fitzgerald
Yale Jen - Laidlaw & Company
Yi Chen - H.C. Wainwright
Operator
Good morning. My name is Josh and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals First Quarter 2022 Financial Results and Recent Corporate Development's Conference Call. There will be a question-and-answer session to follow at the completion of the prepared remarks. Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to George Elston, Chief Financial Officer of EyePoint Pharmaceuticals.
George Elston
Thank you, Josh and thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals' first quarter 2022 financial results and recent corporate development.
With me today is Nancy Lurker, President and Chief Executive Officer; Dr. Jay Duker, Chief Operating Officer; and Scott Jones, Chief Commercial Officer. Nancy will begin with a review of recent corporate updates. Dr. Duker will then discuss pipeline developments for EYP-1901, and Scott will comment on our Q1 2022 commercial activities. I will close the momentary on the first quarter financial results and then we'll open up the call for your questions.
Earlier this morning, we issued a press release detailing our financial results as well as commercial and operational development. A copy of the release can be found on the Investor Relations tab on the corporate website, www.eyepointpharma.com.
Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. These include statements about our future expectations; clinical developments and regulatory matters and timelines; the potential success of our products and product candidates; financial projections; and plans and prospects.
Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC and other filings that we may make with the SEC in the future.